IMPAX Laboratories, Inc. (IPXL) Launches Authorized Generic of Zomig (zolmitriptan) Tablets and Orally Disintegrating Tablets in the U.S.
5/17/2013 9:46:12 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
HAYWARD, Calif.--(BUSINESS WIRE)--Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that its generics division, Global Pharmaceuticals, commenced shipment of authorized generic Zomig® (zolmitriptan) tablets and orally disintegrating tablets, 2.5 mg and 5 mg, in the U.S., as part of a Distribution, License, Development and Supply Agreement with AstraZeneca UK Limited (AstraZeneca).
Help employers find you! Check out all the jobs and post your resume.
comments powered by